The short version of acylated peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
=== Market size === Fine chemicals account for about 4% of the universe of chemicals. The chemical industry, valued at $2,500 billion, is dominated mainly by oil-, gas-, and mineral-derived commodities (~40%) and a large variety of specialty chemicals at the interface between industry and the public (~55%). The global production value of fine chemicals is estimated at $85 billion, of which about 2/3, or $55 billion, are produced captively, with $30 billion representing the global revenues of the fine chemical industry. The corresponding figures for the major user, the pharmaceutical industry, are $32 billion and $23 billion respectively. For a number of reasons, such as the lack of statistical data and the somewhat equivocal definition, it is not possible to exactly determine the size of the fine chemical market.
== Synthesis == Etonitazene and related nitazene opioids were discovered in the late 1950s, by a team of Swiss researchers working at the pharmaceutical firm CIBA (now Novartis). One of the first compounds investigated by the Swiss team was 1-(β-diethylaminoethyl)-2-benzylbenzimidazole, which was found to possess 10% of the analgesic activity of morphine when tested in rodent bioassays. This finding encouraged the group to begin a comprehensive systematic study of 2-benzylbenzimidazoles and to establish the structure-activity relationship of this new family of analgesics. Two general synthetic methods were developed for the preparation of these compounds. The first method involved the condensation of o-phenylenediamine with para-ethoxy-phenylacetonitrile to form a 2-benzylbenzimidazole. The benzimidazole is then alkylated with the desired 1-chloro-2-dialkylaminoethane, forming the final product. This particular procedure was most useful for the preparation of benzimidazoles that lacked substituents on the benzene rings. A diagram of this method is displayed below.
=== Bovine β-casomorphin 9 === Structure: YPFPGPIXN X is H (histidine) in A1 and P (proline) in A2. Produced from both A1 and A2. Opioid agonist, but apparently without the detrimental effect of bBCM7 in cell cultures and animal models, and in fact considered potentially beneficial.
== Metabolome databases == Because an organism's metabolome is largely defined by its genome, different species will have different metabolomes. Indeed, the fact that the metabolome of a tomato is different from the metabolome of an apple is the reason why these two fruits taste so different. Furthermore, different tissues, different organs and biofluids associated with those organs and tissues can also have distinctly different metabolomes. The fact that different organisms and different tissues/biofluids have such different metabolomes has led to the development of a number of organism-specific and biofluid-specific metabolome databases. Some of the better known metabolome databases include the Human Metabolome Database or HMDB, the Yeast Metabolome Database or YMDB, the E. coli Metabolome Database or ECMDB, the Arabidopsis metabolome database or AraCyc as well as the Urine Metabolome Database, the Cerebrospinal Fluid (CSF) Metabolome Database and the Serum Metabolome Database. The latter three databases are specific to human biofluids. A number of very popular general metabolite databases also exist including KEGG, MetaboLights, the Golm Metabolome Database, MetaCyc, LipidMaps and Metlin. Metabolome databases can be distinguished from metabolite databases in that metabolite databases contain lightly annotated or synoptic metabolite data from multiple organisms while metabolome databases contain richly detailed and heavily referenced chemical, pathway, spectral and metabolite concentration data for specific organisms.
Sources: en.wikipedia.org
Threonine–tRNA ligase 1, cytoplasmic, also called threonyl-tRNA synthetase 1, is an enzyme that in humans is encoded by the TARS1 gene. Like its relatives, TARS2 and TARS3, this enzyme functions as a threonine–tRNA ligase, which means it attaches the animo acid threonine to its corresponding transfer RNA as part of RNA-to-protein translation.
Iodine-135 is a neutron-rich isotope of iodine with a half-life of 6.58 hours, and important to nuclear reactor physics. It is produced in relatively large amounts as a fission product, and decays to xenon-135, which is a nuclear poison with the largest known thermal neutron cross section, which is a cause of multiple complications in the control of nuclear reactors. The process of buildup of xenon-135 from accumulated iodine-135 can temporarily preclude restarting a reactor that has been shut down. This is known as xenon poisoning or "falling into an iodine pit".
== Positive feedback loops == For many intracrines, once they stimulate the upregulation of a gene, a positive feedback loop is initiated. The intracrine promotes cell proliferation and stimulates further intracellular signaling, leading to increased synthesis and release of the intracrine itself, thereby reinforcing the loop. In multicellular organisms, an intracrine may also be secreted, causing neighboring cells to proliferate and enter a similar positive feedback loop. This mechanism results in a coordinated response that contributes to tissue growth and development.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.